Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country wher